If you observe teams at a medtech organization preparing for an upcoming quarterly review or strategic meeting, you will often see a common scene - teams pulling out accounts and contact history from different places. This includes disconnected systems, personal notes along with a shared spreadsheet the team maintains, and a set of emails. ... Read this blog

The adoption of life sciences-specific CRM built around HCP engagement is growing faster. It is enabling teams to look for more data-driven, structured, and compliant ways to manage relationships. ... Read this blog

For MSL teams, every HCP relationship carries a history, context, and engagement need. As teams expand their networks, managing these details consistently can become difficult without the right infrastructure. ... Read this blog

Emerging biotech companies face a different problem related to KOL management than large life sciences companies do, and it is not just a matter of scale. ... Read this blog

Medical Affairs is one of the most HCP-centric functions within life sciences. Every part of the process, from identifying the right experts to driving engagement and measuring its impact depends on how well a team understands and manages its relationships with healthcare professionals. When relationship data is spread across spreadsheets, inboxes, and disconnected systems, even experienced MSL and Medical Affairs teams struggle to see the full picture. ... Read this blog

Medical affairs has become a more accountable and visible function within the broader organization. Hence, the role of Medical Science Liaisons has also evolved considerably. The growing complexity of therapeutic areas means a single trial readout or data release can reshape an entire engagement strategy overnight. So there’s a little room for generic targeted outreach. Yet most teams are still operating with processes built for an earlier version of the role that was focused more on relationship management and less on strategic accountability. ... Read this blog

Choosing a CRM for life sciences teams once meant picking a system that stores contacts, tracks interactions, and generates a few reports for leadership. Today that calculus no longer holds. Medical Affairs, Commercial, and Field teams now manage increasingly complex stakeholder ecosystems, from Key Opinion Leaders and investigators to advocacy groups and cross-functional internal teams. ... Read this blog

Agentic AI in life sciences refers to AI systems that can independently plan, reason, retrieve trusted scientific data, and execute multi-step workflows to achieve a defined objective. It enables pharmaceutical, biotech, medtech, and diagnostics teams to automate complex tasks, access actionable insights faster, and make more informed decisions with minimal manual intervention. ... Read this blog

Medical congresses are among the most information-dense environments in life sciences. Within the span of three to five days, a single event can bring out pivotal clinical trial readouts, shift the scientific consensus in a therapeutic area, reveal a competitor's evolving narrative, and elevate a handful of emerging voices into influential KOLs. Yet for most organisations, a significant portion of that value goes uncaptured. ... Read this blog

In the life sciences industry, the companies who become successful aren't those with the greatest KOL networks but the ones that get their KOL management strategy right. They win because they built the right relationships, at the right stage, with the right depth of engagement. For mid-sized biopharma companies, this is the growth phase where that distinction matters most, where KOL strategy either becomes a genuine competitive advantage or never fully delivers. This guide breaks down exactly how to get it right and where to begin. ... Read this blog

Most life sciences teams already know who the top KOLs are in their therapeutic areas. The real challenge today is understanding which experts matter for which objective, when to engage them, and how to build meaningful relationships at scale. ... Read this blog

Most life sciences teams have a KOL strategy. Far fewer have one that holds up when the product pipeline expands, geographies multiply, and the same shortlist of familiar names stops being enough. ... Read this blog